Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression.

Increasing evidence supports a propensity towards inflammation in Alzheimer's disease (AD) pathogenesis. In our previous studies we observed high levels of IL-16, IL-18 and TGF-beta1 mRNA expression in monocyte-macrophages of the peripheral blood of AD patients. The aim of this investigation was to determine the plasma levels of IL-12, IL-16, IL-18 and TGF-beta1 in AD patients at different stages of the disease and to correlate the production of these cytokines with the disease progression. The levels of IL-12, IL-16, IL-18 and TGF-beta1 resulted higher in AD-mild patients, were slightly lower in AD-moderate patients, whereas no significant difference was observed between AD-severe patients and non-demented age-matched subjects. The correlation values between cytokine plasma levels were dependent on the disease progression. Our data indicate that plasma levels of these inflammatory molecules follow the degree of AD suggesting a gradual decline of immune responsiveness in AD.

[1]  R. Comolli,et al.  Decrease of TGF-β1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease , 2002, Experimental Gerontology.

[2]  W. Fridman,et al.  Interleukin-18: biological properties and clinical implications. , 2000, European cytokine network.

[3]  T. Bártfai,et al.  Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment , 2004, Neuroscience.

[4]  D. Kögel,et al.  TGF-β1 activates two distinct type I receptors in neurons , 2005, The Journal of Cell Biology.

[5]  D. Gambi,et al.  Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines , 2004, Journal of Neuroimmunology.

[6]  C. Cotman,et al.  Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies , 1993 .

[7]  T. Joh,et al.  Cultures of astrocytes and microglia express interleukin 18. , 1999, Brain research. Molecular brain research.

[8]  H. Lassmann,et al.  APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's Disease , 1996, Neurobiology of Aging.

[9]  J. Aldenhoff,et al.  The calcium response of human T lymphocytes is decreased in aging but increased in Alzheimer’s dementia , 1999, Biological Psychiatry.

[10]  V. Haroutunian,et al.  Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. , 2000, Archives of neurology.

[11]  B. Winblad,et al.  Neuronal expression of caspase-1 immunoreactivity in the rat central nervous system , 2004, Journal of Neuroimmunology.

[12]  Anders Wallin,et al.  Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia , 2002, Neurobiology of Aging.

[13]  E. Mackenzie,et al.  Transforming Growth Factor-β1 Potentiates Amyloid-β Generation in Astrocytes and in Transgenic Mice* , 2003, The Journal of Biological Chemistry.

[14]  N. Bannert,et al.  Cutting Edge: CD4 Is Not Required for the Functional Activity of IL-161 , 2000, The Journal of Immunology.

[15]  F. Paoletti,et al.  Increased plasma levels of soluble CD40, together with the decrease of TGFβ1, as possible differential markers of Alzheimer disease , 2004, Experimental Gerontology.

[16]  Y. Stern,et al.  Hospitalization and Alzheimer's disease: results from a community-based study. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[17]  M. Malaguarnera,et al.  Interleukin‐18 and transforming growth factor‐beta 1 plasma levels in Alzheimer’s disease and vascular dementia , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.

[18]  P. Mecocci,et al.  Oxidative damage to DNA in lymphocytes from AD patients , 1998, Neurology.

[19]  Lawrence Da.  Transforming growth factor-beta: a general review. , 1996, European cytokine network.

[20]  F. Nicoletti,et al.  Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia , 2006, The European journal of neuroscience.

[21]  K. Blennow,et al.  Intrathecal inflammation precedes development of Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[22]  J Marshall,et al.  Cerebral blood flow in dementia. , 1975, Archives of neurology.

[23]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[24]  Elisabeth Kapaki,et al.  Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia , 2006, Journal of the Neurological Sciences.

[25]  A. Thomson.  The cytokine handbook , 1994 .

[26]  P. Lipton,et al.  Ischemic cell death in brain neurons. , 1999, Physiological reviews.

[27]  K. Blennow,et al.  Increased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer’s disease , 2004, Neuroscience Letters.

[28]  J. Schwab,et al.  Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages , 2001, Journal of Neuroimmunology.

[29]  C D Marsden,et al.  Mini-mental state examination in neurological patients. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[30]  G. Annoni,et al.  Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.

[31]  F. Giubilei,et al.  T Cell Response to Amyloid-β and to Mitochondrial Antigens in Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[32]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[33]  R. Cacabelos,et al.  Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals , 1999, Journal of Neuroimmunology.

[34]  H. Schluesener,et al.  Leukocyte chemotactic factor, a natural ligand to CD4, is expressed by lymphocytes and microglial cells of the MS plaque , 1996, Journal of neuroscience research.

[35]  D. Feinstein,et al.  Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised , 2004, Journal of Neuroinflammation.

[36]  A. J. Valente,et al.  Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappaB-dependent PTEN activation. , 2006, Biochemical and biophysical research communications.

[37]  N. Rothwell,et al.  Interleukin‐18 induces expression and release of cytokines from murine glial cells: interactions with interleukin‐1β , 2003, Journal of neurochemistry.

[38]  L. Mucke,et al.  Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease , 1997, Nature.

[39]  K. Suk,et al.  Regulation of IL-18 production by IFN gamma and PGE2 in mouse microglial cells: involvement of NF-kB pathway in the regulatory processes. , 2001, Immunology letters.

[40]  Dc Washington.  Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .

[41]  J. Cummings,et al.  Telomere shortening in T cells correlates with Alzheimer’s disease status , 2003, Neurobiology of Aging.

[42]  H. Okamura,et al.  Cloning of a new cytokine that induces IFN-γ production by T cells , 1995, Nature.

[43]  N. Rothwell,et al.  Detection of the interleukin 18 family in rat brain by RT-PCR. , 2000, Brain research. Molecular brain research.

[44]  R. Mrak,et al.  Welcome to the Journal of Neuroinflammation! , 2004, Journal of Neuroinflammation.